BTIG analyst Jeet Mukherjee has reiterated their bullish stance on MNPR stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jeet Mukherjee’s rating is based on the promising long-term efficacy and safety data for ALXN1840 presented by Monopar Therapeutics Inc. The data demonstrated sustained neurological benefits for patients over a six-year period, with significant improvements observed in both Phase 2 and Phase 3 studies. Notably, patients who switched from standard of care to ALXN1840 showed greater neurological improvements compared to those who remained on standard treatments.
Furthermore, the safety profile of ALXN1840 is favorable, with a low incidence of serious adverse events related to the drug. This positive benefit-risk profile, combined with the potential for addressing concerns about copper balance and elimination, supports the undervaluation of ALXN1840. Mukherjee reiterates a Buy rating, seeing the recent data as strengthening the case for a potential NDA submission in early 2026, and maintains a price target of $87.
Mukherjee covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Monopar Therapeutics Inc, and Nurix Therapeutics. According to TipRanks, Mukherjee has an average return of 0.1% and a 53.57% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.